Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
MuReva Phototherapy Presents Data during 2025 ASTRO Meeting Confirming Safety and Efficacy of the Company's LED-based Photobiomodulation Therapy Device

From MuReva Phototherapy

By

October 28, 2025

MuReva Phototherapy Presents Data during 2025 ASTRO Meeting Confirming Safety and Efficacy of the Company's LED-based Photobiomodulation Therapy Device

MuReva Phototherapy Presents Data during 2025 ASTRO Meeting Confirming Safety and Efficacy of the Company's LED-based Photobiomodulation Therapy Device
BRECKSVILLE, Ohio, Oct. 28, 2025 - MuReva Phototherapy announced the oral presentation of clinical data demonstrating the safety and efficacy of the company's LED-based photobiomodulation (PBM) therapy device during the 2025 American Society for Radiation Oncology (ASTRO) Meeting held in San Francisco. This U.S. multicenter study included 85 patients undergoing radiation therapy for head and neck cancer who were randomized to either a treatment arm using the MuReva OM to deliver intra-oral PBM therapy or to a sham (placebo) control arm. Results demonstrated that the use of the MuReva device was safe, well tolerated, with clinically meaningful outcomes. Treatment with MuReva led to significant reductions in the incidence of severe oral mucositis during radiation treatment and two-weeks post treatment compared with the sham control group.

View original article on murevapt.com

Most Recent

Timeshifter Raises New Funding to Scale Circadian Technology Across Travel, Shift Work and Healthcare

Timeshifter Raises New Funding to Scale Circadian Technology Across Travel, Shift Work and Healthcare

PR Newswire reported that Timeshifter has raised 5.3 million dollars total to date and announced a new round led by Skip Capital.

Apr 15, 2026

The 96% Blind Spot: Oso and Cyera Research reveal unused permissions lying in wait for AI agents

The 96% Blind Spot: Oso and Cyera Research reveal unused permissions lying in wait for AI agents

Oso and Cyera published joint research finding that enterprise workers leave 96% of granted permissions unused, creating AI-agent access risk.

Mar 17, 2026

American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy's LED-based Photobiomodulation Therapy Device

American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy's LED-based Photobiomodulation Therapy Device

AMA CPT Editorial Panel approved new Category III CPT code 1011T for MuReva's photobiomodulation therapy procedures

Dec 15, 2025

Leantime joins Techstars NYC 2023 Winter cohort and becomes a Techstars portfolio company

Leantime joins Techstars NYC 2023 Winter cohort and becomes a Techstars portfolio company

Leantime announced it had joined the Techstars NYC 2023 Winter cohort and become a Techstars portfolio company.

Nov 15, 2023

Similar Posts

American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy's LED-based Photobiomodulation Therapy Device

American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy's LED-based Photobiomodulation Therapy Device

AMA CPT Editorial Panel approved new Category III CPT code 1011T for MuReva's photobiomodulation therapy procedures

Dec 15, 2025

MuReva Phototherapy presents data from pilot study of company's photobiomodulation device during 2023 MASCC Annual Meeting

MuReva Phototherapy presents data from pilot study of company's photobiomodulation device during 2023 MASCC Annual Meeting

MuReva Phototherapy presented data from a pilot trial using the company's LED-based intraoral Photobiomodulation device for daily use in head and neck cancer patients during MASCC 2023

Jun 22, 2023

MuReva Phototherapy presents data from pilot study of Head and Neck Cancer Patients Treated Daily with an Intraoral Photobiomodulation Device during the ASTRO 2023 Annual Meeting

MuReva Phototherapy presents data from pilot study of Head and Neck Cancer Patients Treated Daily with an Intraoral Photobiomodulation Device during the ASTRO 2023 Annual Meeting

MuReva Phototherapy presented data from a pilot prospective study of the company's Intraoral Photobiomodulation Device during the ASTRO 65th Annual Meeting in San Diego

Oct 2, 2023

Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app

Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app

Nue Life Health is a U.S.-based telemedicine startup that combines psychedelic-assisted therapies and a health tracking app. Previously, the app was only offered as part of its own internal service. However, the startup is now opening up its “Nue app” and its “Nue score” available for free to any patient undergoing ketamine therapy, not just […]

Jun 15, 2023

Most Recent

Timeshifter Raises New Funding to Scale Circadian Technology Across Travel, Shift Work and Healthcare

Timeshifter Raises New Funding to Scale Circadian Technology Across Travel, Shift Work and Healthcare

PR Newswire reported that Timeshifter has raised 5.3 million dollars total to date and announced a new round led by Skip Capital.

Apr 15, 2026

The 96% Blind Spot: Oso and Cyera Research reveal unused permissions lying in wait for AI agents

The 96% Blind Spot: Oso and Cyera Research reveal unused permissions lying in wait for AI agents

Oso and Cyera published joint research finding that enterprise workers leave 96% of granted permissions unused, creating AI-agent access risk.

Mar 17, 2026

American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy's LED-based Photobiomodulation Therapy Device

American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy's LED-based Photobiomodulation Therapy Device

AMA CPT Editorial Panel approved new Category III CPT code 1011T for MuReva's photobiomodulation therapy procedures

Dec 15, 2025

Leantime joins Techstars NYC 2023 Winter cohort and becomes a Techstars portfolio company

Leantime joins Techstars NYC 2023 Winter cohort and becomes a Techstars portfolio company

Leantime announced it had joined the Techstars NYC 2023 Winter cohort and become a Techstars portfolio company.

Nov 15, 2023

Similar Posts

American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy's LED-based Photobiomodulation Therapy Device

American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy's LED-based Photobiomodulation Therapy Device

AMA CPT Editorial Panel approved new Category III CPT code 1011T for MuReva's photobiomodulation therapy procedures

Dec 15, 2025

MuReva Phototherapy presents data from pilot study of company's photobiomodulation device during 2023 MASCC Annual Meeting

MuReva Phototherapy presents data from pilot study of company's photobiomodulation device during 2023 MASCC Annual Meeting

MuReva Phototherapy presented data from a pilot trial using the company's LED-based intraoral Photobiomodulation device for daily use in head and neck cancer patients during MASCC 2023

Jun 22, 2023

MuReva Phototherapy presents data from pilot study of Head and Neck Cancer Patients Treated Daily with an Intraoral Photobiomodulation Device during the ASTRO 2023 Annual Meeting

MuReva Phototherapy presents data from pilot study of Head and Neck Cancer Patients Treated Daily with an Intraoral Photobiomodulation Device during the ASTRO 2023 Annual Meeting

MuReva Phototherapy presented data from a pilot prospective study of the company's Intraoral Photobiomodulation Device during the ASTRO 65th Annual Meeting in San Diego

Oct 2, 2023

Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app

Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app

Nue Life Health is a U.S.-based telemedicine startup that combines psychedelic-assisted therapies and a health tracking app. Previously, the app was only offered as part of its own internal service. However, the startup is now opening up its “Nue app” and its “Nue score” available for free to any patient undergoing ketamine therapy, not just […]

Jun 15, 2023